Drugs / Radezolid
Radezolid
also known as
AND RX-01_667 · Radezolid hcl · RADEZOLID HYDROCHLORIDE · RX-01 · RX-013 · RX-01_667 · RX-103 · RX-1741 · +2 more
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00646958 | Dec 2007 → Apr 2008 | abscess, skin disease caused by bacterial infection, staphylococcal infection, streptococcal infection | Melinta Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00640926 | Oct 2007 → Mar 2009 | pneumonia | Melinta Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Radezolid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00646958 ↗ |
| Known as | AND RX-01_667 | ChEMBL registry synonym — accepted as the source's own label CHEMBL455461 ↗ |
| Known as | Radezolid hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL455461 ↗ |
| Known as | RADEZOLID HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL455461 ↗ |
| Known as | RX-01 | ChEMBL registry synonym — accepted as the source's own label CHEMBL455461 ↗ |
| Known as | RX-013 | ChEMBL registry synonym — accepted as the source's own label CHEMBL455461 ↗ |
| Known as | RX-01_667 | ChEMBL registry synonym — accepted as the source's own label CHEMBL455461 ↗ |
| Known as | RX-103 | ChEMBL registry synonym — accepted as the source's own label CHEMBL455461 ↗ |
| Known as | RX-1741 | ChEMBL registry synonym — accepted as the source's own label CHEMBL455461 ↗ |
| Known as | RX-1741667 | ChEMBL registry synonym — accepted as the source's own label CHEMBL455461 ↗ |
| Known as | RX-O1_667 | ChEMBL registry synonym — accepted as the source's own label CHEMBL455461 ↗ |
| Modality | Small molecule | “RX-1741, an oxazolidinone antibiotic” NCT00640926 ↗ |
| Route | Oral | “300 mg/day, orally for 7-10 days” NCT00640926 ↗ |